NCT02187107View on ClinicalTrials.gov

A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

September 30, 2005

Study Completion Date

March 31, 2009

Conditions

HIV

Interventions

DRUG

TMC114

300 mg tablets of TMC114 ethanolate with microcrystalline cellulose, colloidal silicon dioxide, crospovidone, magnesium stearate, and Opadry® Orange

DRUG

rtv

100 mg tablet of Norvir®

Trial Locations (11)

Unknown

Darlinghurst

Vienna

Ghent

Copenhagen

Berlin

Hamburg

Hanover

Munich

Szczecin

Saint Petersburg

London

All Listed Sponsors

lead

Tibotec Pharmaceuticals, Ireland

INDUSTRY

NCT02187107 - A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials | Biotech Hunter | Biotech Hunter